- Home
- SERV vs ANAB Comparison
SERV vs ANAB Comparison
Compare SERV & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SERV
- ANAB
- Stock Information
- Founded
- SERV 2017
- ANAB 2005
- Country
- SERV United States
- ANAB United States
- Employees
- SERV N/A
- ANAB N/A
- Industry
- SERV Industrial Specialties
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- SERV Consumer Discretionary
- ANAB Health Care
- Exchange
- SERV Nasdaq
- ANAB Nasdaq
- Market Cap
- SERV 609.5M
- ANAB 621.1M
- IPO Year
- SERV N/A
- ANAB 2017
- Fundamental
- Price
- SERV $9.71
- ANAB $20.22
- Analyst Decision
- SERV Buy
- ANAB Buy
- Analyst Count
- SERV 4
- ANAB 10
- Target Price
- SERV $18.67
- ANAB $48.00
- AVG Volume (30 Days)
- SERV 4.4M
- ANAB 459.5K
- Earning Date
- SERV 08-07-2025
- ANAB 08-06-2025
- Dividend Yield
- SERV N/A
- ANAB N/A
- EPS Growth
- SERV N/A
- ANAB N/A
- EPS
- SERV N/A
- ANAB N/A
- Revenue
- SERV $1,479,483.00
- ANAB $123,164,000.00
- Revenue This Year
- SERV $284.61
- ANAB N/A
- Revenue Next Year
- SERV $580.91
- ANAB $24.39
- P/E Ratio
- SERV N/A
- ANAB N/A
- Revenue Growth
- SERV N/A
- ANAB 304.17
- 52 Week Low
- SERV $4.66
- ANAB $12.21
- 52 Week High
- SERV $24.35
- ANAB $40.70
- Technical
- Relative Strength Index (RSI)
- SERV 43.35
- ANAB 34.66
- Support Level
- SERV $8.87
- ANAB $19.48
- Resistance Level
- SERV $10.53
- ANAB $20.35
- Average True Range (ATR)
- SERV 0.60
- ANAB 1.27
- MACD
- SERV -0.09
- ANAB -0.13
- Stochastic Oscillator
- SERV 38.36
- ANAB 18.49
About SERV Serve Robotics Inc. Common Stock
Serve Robotics Inc is developing next-generation robots for last-mile delivery services. It design, develop and operate low-emissions robots on AI-powered robotics mobility platform, that serve people in public spaces, starting with food delivery. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. It has developed an AI-robotics mobility platform, with last-mile delivery in cities as its first application.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).